Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
Top Cited Papers
Open Access
- 26 September 2016
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 17 (11), 1521-1532
- https://doi.org/10.1016/s1470-2045(16)30313-8
Abstract
No abstract availableFunding Information
- Canadian Cancer Society Research Institute (grant number 015469 and 021039)
- National Health and MRC project grant (ID 509094)
This publication has 44 references indexed in Scilit:
- Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951Journal of Clinical Oncology, 2013
- MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-statusActa Neuropathologica, 2012
- Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomasNeuro-Oncology, 2012
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotypeNature, 2012
- IDH1andIDH2Mutations in GliomasNew England Journal of Medicine, 2009
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- A t(1;19)(q10;p10) Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with OligodendrogliomaCancer Research, 2006
- Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)British Journal of Cancer, 2006
- Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesBritish Journal of Cancer, 2003
- Phase II Trial of Temozolomide in Patients With Progressive Low-Grade GliomaJournal of Clinical Oncology, 2003